Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Medrx Co., Ltd. (4586) Price & Analysis

4586 Stock Chart & Stats

¥47.00-¥1.00(-2.08%)
At close: 4:00 PM EDT
JPY 50JPY 55JPY 60JPY 653 Aug17 Aug31 Aug14 Sep28 Sep13 Oct26 Oct
Day’s Range
JPY 46.00 - JPY 48.00
52-Week Range
JPY 46.00 - JPY 136.00
Previous Close
JPY 48.00
Volume
530.50K
Average Volume (3M)
595.61K
Market Cap
JPY 3.29B
Enterprise Value
JPY 2.13B
Total Cash (Recent Filing)
JPY 1.14B
Total Debt (Recent Filing)
JPY 0
Price to Earnings (P/E)
―
Beta
1.37
Next Earnings
Nov 13, 2026
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance Sheet

A zero-debt balance sheet limits fixed financing obligations and reduces solvency pressure during periods of operating weakness. This gives Medrx greater flexibility to preserve resources, pursue development activities, and manage volatility without the added burden of significant interest or refinancing requirements.

Strong Gross Margins

Gross margins in the 85–90% range indicate that Medrx’s transdermal products and technologies can retain substantial value after direct costs. If the company expands revenue, this margin profile could provide meaningful operating leverage, although broader expenses currently prevent that gross profit from becoming earnings.

2025 Revenue Rebound

The sharp 2025 revenue rebound demonstrates that Medrx can generate materially higher sales than in the preceding year. Sustained improvement would broaden the revenue base supporting its development model and could eventually help absorb fixed operating costs, provided growth continues beyond the rebound.

Bears Say

Persistent Deep Losses

Medrx’s revenue growth has not yet translated into profitability, with the net margin deteriorating substantially in 2025. Losses of this scale indicate that operating expenses remain far above the current revenue base, weakening earnings visibility and making a durable path to self-sustaining profits uncertain.

Ongoing Cash Burn

Consistently negative operating and free cash flow shows that Medrx is not currently funding its activities through internally generated cash. Continued cash burn can consume balance-sheet resources and increase reliance on external financing, potentially limiting the company’s ability to sustain development and commercialization efforts.

Volatile Financial Performance

Highly variable revenue and persistently negative returns on equity indicate that Medrx has not yet established a reliable earnings engine. This instability makes planning and capital allocation more difficult, while continued losses risk reducing the effectiveness of shareholder capital even without significant debt.

4586 FAQ

What was Medrx Co., Ltd.’s price range in the past 12 months?
Medrx Co., Ltd. lowest stock price was ¥46.00 and its highest was ¥136.00 in the past 12 months.
What is Medrx Co., Ltd.’s market cap?
Medrx Co., Ltd.’s market cap is ¥3.29B.
When is Medrx Co., Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Medrx Co., Ltd.’s earnings last quarter?
Medrx Co., Ltd. released its earnings results on Aug 07, 2026. The company reported -¥5.25 earnings per share for the quarter.
Is Medrx Co., Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Medrx Co., Ltd. pay dividends?
Medrx Co., Ltd. does not currently pay dividends.
What is Medrx Co., Ltd.’s EPS estimate?
Medrx Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medrx Co., Ltd. have?
Medrx Co., Ltd. has 70,007,600 shares outstanding.
What happened to Medrx Co., Ltd.’s price movement after its last earnings report?
Medrx Co., Ltd. reported an EPS of -¥5.25 in its last earnings report. Following the earnings report the stock price went down -4.412%.
Which hedge fund is a major shareholder of Medrx Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4586
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology